|
Get Financial Filings and Annual Reports for Companies featured on TWST from EasyReports.net
TWST: Reni, you're putting on a biotech conference. Could you tell us
about that?
Dr. Benjamin: By way of background, Rodman & Renshaw is a full-service
investment bank with a focus on small to mid-cap biotechnology and
technology companies. We are committed to the long-term development of
emerging companies through value-added equity research, institutional
sales and trading, strategic advice, and capital raising. Our equity
research, sales and trading efforts cater only to institutional clients
looking to invest in undervalued, under-covered companies with
outstanding technologies. Currently, the biotechnology team consists of
seven PhDs of which four are senior analysts including myself, Elemer
Piros, David Wood and Navdeep Jaikaria. Combined, we cover a wide range
of therapeutic categories including oncology, cardiology, infectious
disease, inflammation and autoimmune diseases. Companies currently under
coverage by the biotech team at Rodman include Aksys (AKSY), Alteon
(ALT), Ariad Pharmaceutical (ARIA), Applied Molecular Evolution (AMEV),
AVI BioPharma (AVII), Cepheid (CPHD), CollaGenex Pharmaceuticals (CGPI),
Cypress Bioscience (CYPB), Dyax (DYAX), Encysive Pharmaceuticals (ENCY),
Genelabs Technologies (GNLB), Genta (GNTA), Geron (GERN), InKine
Pharmaceuticals (INKP), Isis Pharmaceuticals (ISIS), Repligen (RGEN),
Rita Medical Systems (RITA), SuperGen (SUPG), Tanox (TNOX) and United
Therapeutics (UTHR). As part of Rodman and Renshaw's continued growth
and development, the company acquired all the rights to the Annual
Techvest Healthcare Conference. The conference, to be held in Boston
from October 21-23, 2003, will host over 150 public and private
companies, as well as a large number of institutional and venture
capital investors. TWST: What are you going to do with it?
Dr. Benjamin: In addition to panel discussions with independent experts
helping to sift through complex issues surrounding biotechnology and
thought provoking and vibrant keynote speakers, we will showcase
upcoming growth companies that we believe comprise the next generation
of biotechnology companies. We already have over 150 public and private
companies presenting to a large audience of institutional investors.
Tickers included in this excerpt: AKSY, ALT, AMEV, ARIA, ASCO, AVII, AZN, BGEN, BMRN, CGPI, CPHD, CYPB, DNA, DYAX, ENCY, GENZ, GERN, GNLB, GNTA, INKP, ISIS, MEDI, MLNM, NVS, RGEN, RITA, SUPG, TNOX, UTHR
For more information call (212) 952 7400. The
Wall Street Transcript does not endorse any of the comments made by interviewees, and does
not make stock recommendations.
|
|
 |
